Palatin Technologies Participates In Canaccord Genuity’s 40th Annual Growth Conference
Aug 13, 2020, 16:12 ET CRANBURY, N.J., Aug. 13, 2020 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, announced that it participated in Canaccord Genuity’s 40th Annual Growth Conference in a Fireside Chat today …
Palatin Technologies Participates In Canaccord Genuity’s 40th Annual Growth Conference Read More »